Lawrence Yao1, Adrienne L Yip2, Joseph A Shrader3, Sepehr Mesdaghinia2, Rita Volochayev2, Anna V Jansen2, Frederick W Miller2, Lisa G Rider4. 1. Radiology and Imaging Sciences, Clinical Center. 2. Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences and. 3. Department of Rehabilitation Medicine, Clinical Center, NIH, Bethesda, MD, USA. 4. Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences and riderl@mail.nih.gov.
Abstract
OBJECTIVE: This study examines the utility of MRI, including T2 maps and T2 maps corrected for muscle fat content, in evaluating patients with idiopathic inflammatory myopathy. METHODS: A total of 44 patients with idiopathic inflammatory myopathy, 18 of whom were evaluated after treatment with rituximab, underwent MRI of the thighs and detailed clinical assessment. T2, fat fraction (FF) and fat corrected T2 (fc-T2) maps were generated from standardized MRI scans, and compared with semi-quantitative scoring of short tau inversion recovery (STIR) and T1-weighted sequences, as well as various myositis disease metrics, including the Physician Global Activity, the modified Childhood Myositis Assessment Scale and the muscle domain of the Myositis Disease Activity Assessment Tool-muscle (MDAAT-muscle). RESULTS: Mean T2 and mean fc-T2 correlated similarly with STIR scores (Spearman rs = 0.64 and 0.64, P < 0.01), while mean FF correlated with T1 damage scores (rs = 0.69, P < 0.001). Baseline T2, fc-T2 and STIR scores correlated significantly with the Physician Global Activity, modified Childhood Myositis Assessment Scale and MDAAT-muscle (rs range = 0.41-0.74, P < 0.01). The response of MRI measures to rituximab was variable, and did not significantly agree with a standardized clinical definition of improvement. Standardized response means for the MRI measures were similar. CONCLUSION: Muscle T2, fc-T2 and FF measurements exhibit content validity with reference to semi-quantitative scoring of STIR and T1 MRI, and also exhibit construct validity with reference to several myositis activity and damage measures. T2 was as responsive as fc-T2 and STIR scoring, although progression of muscle damage was negligible during the study. Published by Oxford University Press on behalf of the British Society for Rheumatology 2015. This work is written by US Government employees and is in the public domain in the US.
OBJECTIVE: This study examines the utility of MRI, including T2 maps and T2 maps corrected for muscle fat content, in evaluating patients with idiopathic inflammatory myopathy. METHODS: A total of 44 patients with idiopathic inflammatory myopathy, 18 of whom were evaluated after treatment with rituximab, underwent MRI of the thighs and detailed clinical assessment. T2, fat fraction (FF) and fat corrected T2 (fc-T2) maps were generated from standardized MRI scans, and compared with semi-quantitative scoring of short tau inversion recovery (STIR) and T1-weighted sequences, as well as various myositis disease metrics, including the Physician Global Activity, the modified Childhood Myositis Assessment Scale and the muscle domain of the Myositis Disease Activity Assessment Tool-muscle (MDAAT-muscle). RESULTS: Mean T2 and mean fc-T2 correlated similarly with STIR scores (Spearman rs = 0.64 and 0.64, P < 0.01), while mean FF correlated with T1 damage scores (rs = 0.69, P < 0.001). Baseline T2, fc-T2 and STIR scores correlated significantly with the Physician Global Activity, modified Childhood Myositis Assessment Scale and MDAAT-muscle (rs range = 0.41-0.74, P < 0.01). The response of MRI measures to rituximab was variable, and did not significantly agree with a standardized clinical definition of improvement. Standardized response means for the MRI measures were similar. CONCLUSION: Muscle T2, fc-T2 and FF measurements exhibit content validity with reference to semi-quantitative scoring of STIR and T1 MRI, and also exhibit construct validity with reference to several myositis activity and damage measures. T2 was as responsive as fc-T2 and STIR scoring, although progression of muscle damage was negligible during the study. Published by Oxford University Press on behalf of the British Society for Rheumatology 2015. This work is written by US Government employees and is in the public domain in the US.
Authors: Hee Kyung Kim; Tal Laor; Paul S Horn; Judy M Racadio; Brenda Wong; Bernard J Dardzinski Journal: Radiology Date: 2010-06 Impact factor: 11.105
Authors: William T Triplett; Celine Baligand; Sean C Forbes; Rebecca J Willcocks; Donovan J Lott; Soren DeVos; Jim Pollaro; William D Rooney; H Lee Sweeney; Carsten G Bönnemann; Dah-Jyuu Wang; Krista Vandenborne; Glenn A Walter Journal: Magn Reson Med Date: 2013-09-04 Impact factor: 4.668
Authors: F W Miller; L G Rider; Y L Chung; R Cooper; K Danko; V Farewell; I Lundberg; C Morrison; L Oakley; I Oakley; C Pilkington; J Vencovsky; K Vincent; D L Scott; D A Isenberg Journal: Rheumatology (Oxford) Date: 2001-11 Impact factor: 7.580
Authors: Robert L Janiczek; Giulio Gambarota; Christopher D J Sinclair; Tarek A Yousry; John S Thornton; Xavier Golay; Rexford D Newbould Journal: Magn Reson Med Date: 2011-05-20 Impact factor: 4.668
Authors: Chester V Oddis; Ann M Reed; Rohit Aggarwal; Lisa G Rider; Dana P Ascherman; Marc C Levesque; Richard J Barohn; Brian M Feldman; Michael O Harris-Love; Diane C Koontz; Noreen Fertig; Stephanie S Kelley; Sherrie L Pryber; Frederick W Miller; Howard E Rockette Journal: Arthritis Rheum Date: 2013-02
Authors: S M Maillard; R Jones; C Owens; C Pilkington; P Woo; L R Wedderburn; K J Murray Journal: Rheumatology (Oxford) Date: 2004-02-24 Impact factor: 7.580
Authors: Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto Journal: Nat Rev Rheumatol Date: 2018-04-12 Impact factor: 20.543
Authors: Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider Journal: J Rheumatol Date: 2019-08-01 Impact factor: 4.666
Authors: Iago Pinal-Fernandez; Maria Casal-Dominguez; John A Carrino; Arash H Lahouti; Pari Basharat; Jemima Albayda; Julie J Paik; Shivani Ahlawat; Sonye K Danoff; Thomas E Lloyd; Andrew L Mammen; Lisa Christopher-Stine Journal: Ann Rheum Dis Date: 2016-09-20 Impact factor: 19.103
Authors: Matthew Farrow; Andrew J Grainger; Ai Lyn Tan; Maya H Buch; Paul Emery; John P Ridgway; Thorsten Feiweier; Steven F Tanner; John Biglands Journal: Br J Radiol Date: 2019-07-12 Impact factor: 3.039